Hongene introduces a breakthrough chemoenzymatic ligation technology to address critical bottlenecks in RNA drug manufacturing. Traditional solid-phase oligonucleotide synthesis (SPOS) suffers from low yield, excessive raw material consumption (3,000 kg raw material/kg API), and poor sustainability. Hongene’s solution delivers:
- High purity & yield: siRNA purity ≥97% (vs. SPOS’s ~90%), yield up to 43% (vs. SPOS’s ~50%);
- Scalable & sustainable: Enables kilogram-scale GMP production, reduces raw material use by 99%, and uses water-based reactions;
-
Clinically validated: Successfully manufactured PCSSK9 siRNA (e.g., Inclisiran) for clinical development across cardiovascular drugs.
This platform provides a scalable, sustainable, and clinically proven manufacturing solution for next-generation RNA therapeutics (siRNA, sgRNA), projected to meet >10 tons of siRNA API demand by 2030.
Download the flyer for full mass spectrometry data, impurity control profiles, and process details.